http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novocure Reports Second Quarter 2023 Financial Results
-
ROSEN, NATIONAL TRIAL COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
-
Novocure (NVCR) Reports Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
-
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
-
Novocure to Report Second Quarter 2023 Financial Results
-
Zai Lab (ZLAB) and Novocure (NVCR) Report LUNAR Phase 3 Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival
-
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
-
Novocure (NVCR) Reports LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Can
-
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based
-
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
-
Novocure Reports First Quarter 2023 Financial Results
-
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
-
Novocure to Report First Quarter 2023 Financial Results
-
Novocure (NVCR) Appoints Kristin Stafford to its Board
-
Kristin Stafford Joins Novocure Board of Directors
-
Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
-
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
-
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
-
Novocure (NVCR) Appoints Allyson J. Ocean to its Board
-
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
-
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
-
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
-
Novocure (NVCR) Announces Organizational Changes
-
Novocure Announces Organizational Changes to Prepare for Future Growth
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Announce LUNAR Study Met Primary Overall Survival Endpoint
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Novocure (NVCR) Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
-
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
-
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
-
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
-
Novocure (NVCR) Secures CE Mark for New Array
-
Novocure Secures CE Mark for New Array
-
Novocure Reports Third Quarter 2022 Financial Results
-
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
-
Novocure (NVCR) Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in JMCB
-
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
-
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
-
Novocure to Report Third Quarter 2022 Financial Results
-
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
-
Novocure to Participate in Upcoming Investor Conferences
-
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
-
Novocure Reports Second Quarter 2022 Financial Results
-
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

